IGM Biosciences (IGMS) to Release Quarterly Earnings on Wednesday

IGM Biosciences (NASDAQ:IGMS) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect IGM Biosciences to post earnings of ($0.12) per share and revenue of $0.40 million for the quarter.

IGM Biosciences (NASDAQ:IGMS) last issued its quarterly earnings data on Thursday, July 31st. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $1.88. The company had revenue of $143.62 million for the quarter, compared to analyst estimates of $3.20 million. IGM Biosciences had a negative net margin of 36.81% and a negative return on equity of 93.35%. On average, analysts expect IGM Biosciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

IGM Biosciences Stock Performance

NASDAQ IGMS opened at $1.27 on Monday. The stock has a market cap of $76.57 million, a PE ratio of -1.41 and a beta of 0.60. The firm has a 50-day moving average of $1.27 and a 200-day moving average of $1.28. IGM Biosciences has a 52-week low of $0.92 and a 52-week high of $22.50.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut IGM Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, June 7th. Two investment analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. According to data from MarketBeat.com, IGM Biosciences presently has an average rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of IGM Biosciences

A number of institutional investors have recently bought and sold shares of IGMS. AQR Capital Management LLC bought a new stake in IGM Biosciences during the first quarter worth about $275,000. Acadian Asset Management LLC acquired a new position in shares of IGM Biosciences in the 1st quarter valued at approximately $97,000. Finally, Invesco Ltd. bought a new stake in shares of IGM Biosciences during the 1st quarter worth approximately $42,000. Institutional investors own 42.79% of the company’s stock.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.